Allelic variation in HLA‐DRB1 is associated with development of antidrug antibodies in cancer patients treated with atezolizumab that are neutralizing in vitro

The treatment of diseases with biologic agents can result in the formation of antidrug antibodies (ADA). Although drivers for ADA formation are unknown, a role for antigen presentation is likely, and variation in human leukocyte antigen (HLA) genes has been shown to be associated with occurrence of...

Descripción completa

Detalles Bibliográficos
Autores principales: Hammer, Christian, Ruppel, Jane, Kamen, Lynn, Hunkapiller, Julie, Mellman, Ira, Quarmby, Valerie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9199883/
https://www.ncbi.nlm.nih.gov/pubmed/35263013
http://dx.doi.org/10.1111/cts.13264

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9199883/
https://www.ncbi.nlm.nih.gov/pubmed/35263013
http://dx.doi.org/10.1111/cts.13264

Ejemplares similares